Patents by Inventor Jang Ming

Jang Ming has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240364706
    Abstract: A communication device includes a transceiver and a control circuit. The control circuit determines whether to transmit a second MKPDU in advance according to a member identifier of a peer device carried by a received first MKPDU and one or more lists maintained by the communication device. When the member identifier of the peer device is not recorded in the one or more lists, the control circuit determines to transmit the second MKPDU in advance. When the control circuit determines to transmit the second MKPDU in advance, the control circuit generates the second MKPDU, encodes the second MKPDU to generate a frame, and transmits a signal carrying the frame through the transceiver, wherein a time interval between the transmission of the signal and a previous transmission performed by the transceiver is less than a predetermined transmission period.
    Type: Application
    Filed: March 12, 2024
    Publication date: October 31, 2024
    Applicant: Realtek Semiconductor Corp.
    Inventors: Yu-Fei Chou, Yang-Lin Cheng, Ming-Dao Chen, Jang-Ming Li
  • Patent number: 10746651
    Abstract: The present invention provides an optical method for predicting treatment response, survival and recurrence of esophageal cancer patients, comprising analyzing the spectral signatures of patient's tumor tissue spectra. By the features of the present invention, the prediction result achieves the sensitivity of 75% and specificity of 73.3% in concurrent chemoradiotherapy (CCRT) response; the survival prediction rate achieves the sensitivity of 100%; the recurrence prediction rate achieves the sensitivity of 85.7%.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 18, 2020
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Jang-Ming Lee, I-Jen Hsu, Max Ti-Kuang Hou, Pei-Wen Yang
  • Publication number: 20190017925
    Abstract: The present invention provides an optical method for predicting treatment response, survival and recurrence of esophageal cancer patients, comprising analyzing the spectral signatures of patient's tumor tissue spectra. By the features of the present invention, the prediction result achieves the sensitivity of 75% and specificity of 73.3% in concurrent chemoradiotherapy (CCRT) response; the survival prediction rate achieves the sensitivity of 100%; the recurrence prediction rate achieves the sensitivity of 85.7%.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 17, 2019
    Inventors: JANG-MING LEE, I-JEN HSU, MAX TI-KUANG HOU, PEI-WEN YANG
  • Patent number: 9208746
    Abstract: A signal transmission system of electronic display devices includes a plurality of electronic display devices and a wireless signal transmission device. The wireless signal transmission device broadcasts a first packet data to the electronic display device. The first packet data comprises an access control address list, and the access control address list comprises the MAC address of a first group of electronic display device. When the wireless signal transmission device receives an acknowledgement (ACK) message from at least a first electronic display device of the first group of electronic display devices, the wireless signal transmission device changes the method of transmission from broadcast to unicast in order to transmit second packet data to the first electronic display device, wherein the second packet data comprises video packet data.
    Type: Grant
    Filed: December 24, 2012
    Date of Patent: December 8, 2015
    Assignee: Nuvoton Technology Corporation
    Inventors: Mu-Lin Chao, Jang-Ming Liang
  • Publication number: 20130017961
    Abstract: The present invention relates to novel genetic markers associated with response of a patient with esophageal cancer (ECa) to chemoradiation therapy, and particularly to methods and kits for predicting an ECa patient's response to chemoradiation therapy by genotyping of the markers.
    Type: Application
    Filed: August 13, 2012
    Publication date: January 17, 2013
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Pei-Chun Chen, Yen-Ching Chen, Liang-Chuan Lai, Mong-Hsun Tsai, Shin-Kuang Chen, Pei-Wen Yang, Jang-Ming Lee, Eric Y. Chuang, Chuhsing K. Hsiao
  • Patent number: 8268562
    Abstract: The present invention relates to novel genetic markers associated with response of a patient with esophageal cancer (ECa) to chemoradiation therapy, and particularly to methods and kits for predicting an ECa patient's response to chemoradiation therapy by genotyping of the markers.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: September 18, 2012
    Assignee: National Taiwan University
    Inventors: Pei-Chun Chen, Yen-Ching Chen, Liang-Chuan Lai, Mong-Hsun Tsai, Shin-Kuang Chen, Pei-Wen Yang, Jang-Ming Lee, Eric Y. Chuang, Chuhsing K. Hsiao
  • Publication number: 20110091871
    Abstract: The present invention relates to novel genetic markers associated with response of a patient with esophageal cancer (ECa) to chemoradiation therapy, and particularly to methods and kits for predicting an ECa patient's response to chemoradiation therapy by genotyping of the markers.
    Type: Application
    Filed: October 20, 2009
    Publication date: April 21, 2011
    Applicant: National Taiwan University
    Inventors: Pei-Chun Chen, Yen-Ching Chen, Liang-Chuan Lai, Mong-Hsun Tsai, Shin-Kuang Chen, Pei-Wen Yang, Jang-Ming Lee, Eric Y. Chuang, Chuhsing K. Hsiao
  • Publication number: 20050153519
    Abstract: A method of reducing oxide thickness variations in a STI pattern that includes both a dense trench array and a wide trench is described. A first HDP CVD step with a deposition/sputter (D/S) ratio of 9.5 is used to deposit a dielectric layer with a thickness that is 120 to 130% of the shallow trench depth. An etch back is performed in the same CVD chamber with NF3, SiF4 or NF3 and SiF4 to remove about 40 to 50% of the initial dielectric layer. A second HDP CVD step with a D/S ratio of 16 deposits an additional thickness of dielectric layer to a level that is slightly higher than after the first deposition. The etch back and second deposition form a smoother dielectric layer surface which enables a subsequent planarization step to provide filled STI features with a minimal amount of dishing in wide trenches.
    Type: Application
    Filed: January 8, 2004
    Publication date: July 14, 2005
    Inventors: Chih-Cheng Lu, Chuan-Ping Hou, Chu-Yun Fu, Chang Wen, Jang Ming
  • Patent number: 6639122
    Abstract: The invention provides a transgenic swine having a transgene encoding a human HLA-DQ or HLA-DR protein, and the swine cells thereof. The invention also provides a graft derived from the transgenic swine, in particular a graft-organ or a graft-tissue, which is useful for grafting into a human recipient.
    Type: Grant
    Filed: September 19, 2000
    Date of Patent: October 28, 2003
    Assignee: Animal Technology Institute Taiwan
    Inventors: Ching-Fu Tu, Chun-Jean Lee, Jang-Ming Lee, Kimiyoshi Tsuji